Gossamer Bio, Inc. — Form 8-K
Filed July 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Gossamer Bio terminated its Collaboration and License Agreement with Chiesi Farmaceutici effective July 23, 2026. Chiesi will pay Gossamer $5 million upfront; Gossamer regains 100% global development and commercialization control of seralutinib (previously 50/50 U.S. profit-share with Chiesi, plus Chiesi ex-U.S. royalty rights). In exchange, Chiesi retains a capped royalty on worldwide net sales (cap amount redacted) plus unspecified regulatory and commercial milestone payments. Gossamer also received regulatory feedback supporting planned NDA submission in September 2026.
Why this rating
Reacquisition restores full strategic/commercial control and majority economics (~$270M market cap). Eliminates 50/50 U.S. profit-share; high-impact pre-NDA regulatory milestone approaching. Material but not transformational alone.
See more from July 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.